Les stratégies thérapeutiques péri-opératoires

Treatment of stage III N2 NSCLC remains controversy. No treatment strategy has proved superiority and different options have to been discussed: surgery followed by adjuvant chemotherapy, neoadjuvant chemotherapy followed by surgery or exclusive concomitant radio-chemotherapy. Several biomarkers are studied to better describe the indications of perioperative chemotherapy: recognize groups of patients with a worse prognosis and distinguish chemosensibility of the tumor.